CastleVax Inc.

About CastleVax Inc.

CastleVax is a clinical-stage company focused on pioneering a mucosal vaccine platform using Newcastle Disease Virus (NDV) to develop safe, effective, and rapidly deployable vaccines for respiratory diseases and pandemics, with a mission to provide innovative vaccines for all humans, everywhere.

Products & Services

Mucosal Vaccine Platform:A state-of-the-art platform using NDV for first-in-class mucosal vaccines that are safe, highly immunogenic, and easy to deliver.

COVID-19 Booster Vaccine:An intranasal NDV-based booster vaccine developed to combat COVID-19, currently advancing into Phase 2b clinical efficacy testing.

Specialties

Mucosal Vaccines Newcastle Disease Virus (NDV) Technology Respiratory Disease Vaccines Pandemic Preparedness

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 34000000 MR: - FA: approximately $34 million FAN: 34000000	D: 2024-07-30 FD: 2024-07-30	1 investors

Grant Latest

2024-07-30

$34.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael Egan

Chief Executive Officer & Chief Scientific Officer

J

Jori Horberg

VP, Operations

D

Danny Wood

Director of Clinical Operations

R

Robert Small

Clinical Program Manager

P

Peter Palese

Co-Founder, Scientific Advisory Board

A

Adolfo García-Sastre

Co-Founder, SAB

View 9 more team members with Pro

Unlock Full Team Directory

Recent News

CastleVax Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised